CD274 and neoplasm: Remarkably and despite the improved clinical outcome in whole body Nr2f6-/- tumour-bearing mice subjected to PD-L1 blocking (combinatorial NR2F6/PD-L1 inhibition group) when directly compared to wild-type mice under mono-therapy, no exacerbated signs of systemic immune-related adverse effects (irAE) such as tissue immune cell infiltrates, colon length or weight change after anti-PD-L1 treatment in Nr2f6-deficient mice were observed during a follow-up period of 3 months ([30] and data not shown).